Substance P-like Immunoreactivity and Somatostatin-like Immunoreactivity in the Ventricular Fluid of Patients with Chronic Pain Syndromes

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 1991 Jan 1

PMID 1834180

Authors

S Jost

C Reuner

J Geiger

M Mohadjer

E Milios

H Cramer

Affiliations

Soon will be listed here.

Abstract

Substance P-like and somatostatin-like immunoreactivities (SPLI and SLI) were determined in ventricular fluid of patients with chronic pain syndromes and in a comparison group with multiple sclerosis, essential tremor, epilepsy and postanoxic myoclonus. Concentrations of SPLI and SLI were non-significantly decreased by 40% and 33% in chronic pain patients as compared with control patients without pain. There were no differences apparent between subgroups of pain patients (deafferentation pain, neoplasia-induced pain, thalamic pain). High pressure liquid chromatography combined with radioimmunoassay showed marked heterogeneity of SPLI and SLI.

References

Nutt J, Mrox E, Leeman S, Williams A, Engel W, Chase T . Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction. Neurology. 1980; 30(12):1280-5. DOI: 10.1212/wnl.30.12.1280. View

Cramer H, Rissler K, Rosler N, Strubel D, Schaudt D, Kuntzmann F . Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. Eur Neurol. 1989; 29(1):1-5. DOI: 10.1159/000116366. View

Doran A, Rubinow D, Wolkowitz O, Roy A, Breier A, Pickar D . Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA. Biol Psychiatry. 1989; 25(4):431-9. DOI: 10.1016/0006-3223(89)90196-0. View

Masaki K . A study of beta-endorphin and substance P level in cerebrospinal fluid on lumbar lesion. Tokushima J Exp Med. 1987; 34(3-4):61-9. View

Massari V, Shults C, Park C, Tizabi Y, Moody T, Chronwall B . Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord. Brain Res. 1985; 343(2):268-74. DOI: 10.1016/0006-8993(85)90744-9. View

Chrubasik J, Meynadier J, Blond S, Scherpereel P, ACKERMAN E, Weinstock M . Somatostatin, a potent analgesic. Lancet. 1984; 2(8413):1208-9. DOI: 10.1016/s0140-6736(84)92761-2. View

Kuraishi Y, Hirota N, Sato Y, Hino Y, Satoh M, Takagi H . Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res. 1985; 325(1-2):294-8. DOI: 10.1016/0006-8993(85)90326-9. View

Urban B, France R, Bissette G, Spielman F, Nemeroff C . Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in chronic pain patients. Pain. 1988; 33(2):169-172. DOI: 10.1016/0304-3959(88)90087-5. View

Randic M, Miletic V . Depressant actions of methionine-enkephalin and somatostatin in cat dorsal horn neurones activated by noxious stimuli. Brain Res. 1978; 152(1):196-202. DOI: 10.1016/0006-8993(78)90148-8. View

10.

Cramer H, Rosler N, Rissler K, Gagnieu M, Renaud B . Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease. Neuropeptides. 1988; 12(3):119-24. DOI: 10.1016/0143-4179(88)90041-8. View

11.

Di Giulio A, Mantegazza P, Dona M, Gorio A . Peripheral nerve lesions cause simultaneous alterations of substance P and enkephalin levels in the spinal cord. Brain Res. 1985; 342(2):405-8. DOI: 10.1016/0006-8993(85)91147-3. View

12.

PERNOW B . Substance P. Pharmacol Rev. 1983; 35(2):85-141. View

13.

Francis P, Bowen D, Lowe S, Neary D, Mann D, Snowden J . Somatostatin content and release measured in cerebral biopsies from demented patients. J Neurol Sci. 1987; 78(1):1-16. DOI: 10.1016/0022-510x(87)90073-6. View

14.

Pearson J, Brandeis L, Cuello A . Depletion of substance P-containing axons in substantia gelatinosa of patients with diminished pain sensitivity. Nature. 1982; 295(5844):61-3. DOI: 10.1038/295061a0. View

15.

Almay B, Johansson F, von Knorring L, Le Greves P, Terenius L . Substance P in CSF of patients with chronic pain syndromes. Pain. 1988; 33(1):3-9. DOI: 10.1016/0304-3959(88)90197-2. View

16.

Cramer H, Wolf A, Rissler K, Weigel K, Ostertag C . Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease. J Neurol. 1985; 232(4):219-22. DOI: 10.1007/BF00313783. View

17.

Steardo L, Barone P, Hunnicutt E . Carbamazepine lowering effect on CSF somatostatin-like immunoreactivity in temporal lobe epileptics. Acta Neurol Scand. 1986; 74(2):140-4. DOI: 10.1111/j.1600-0404.1986.tb04640.x. View

18.

Moochhala S, Sawynok J . Hyperalgesia produced by intrathecal substance P and related peptides: desensitization and cross desensitization. Br J Pharmacol. 1984; 82(2):381-8. PMC: 1987042. DOI: 10.1111/j.1476-5381.1984.tb10773.x. View

19.

Schalling M, Arborelius L, Hokfelt T, Post C . Decrease in gene expression of substance P and thyrotropin releasing hormone (TRH) in rat medulla oblongata following treatment with an antidepressive drug. Acta Physiol Scand. 1988; 134(3):455-6. DOI: 10.1111/j.1748-1716.1988.tb08517.x. View

20.

Otsuka M, Takahashi T . Putative peptide neurotransmitters. Annu Rev Pharmacol Toxicol. 1977; 17:425-39. DOI: 10.1146/annurev.pa.17.040177.002233. View